Genes identified for ovarian cancer prognosis

Share this article:
Genes Identified for Ovarian Cancer Prognosis
Genes Identified for Ovarian Cancer Prognosis

FRIDAY, April 13 (HealthDay News) -- Bimodal genes, or molecular on/off switches, can distinguish clinically relevant subtypes of ovarian cancer and provide ideal targets for diagnostic and prognostic testing, according to a study published online April 11 in the Journal of Molecular Diagnostics.

Dawn N. Kernagis, from Duke University in Durham, N.C., and colleagues used a bimodal discovery algorithm in conjunction with a publicly available ovarian cancer expression microarray data set on 285 ovarian tumors (246 malignant serous [MS] tumors, 20 endometrioid [EM] tumors, 18 low malignant potential [LMP] tumors, and one malignant adenocarcinoma).

The researchers found that robust bimodal expression patterns were identified in genes across all ovarian tumor types and within selected subtypes. Differential expression between LMP versus MS and EM was shown in 73 bimodal genes; 22 bimodal genes distinguished MS from EM; and 14 genes were significantly associated with survival among MS tumors. For patients with a favorable survival score, derived from a combination of these genes, median survival was significantly longer, 65 versus 29 months (hazard ratio, 0.4221). The survival score was validated using two independent data sets [high-grade, advanced-stage serous and advanced-stage ovarian tumors].

"We conclude that genes with bimodal expression patterns not only define clinically relevant molecular subtypes of ovarian carcinoma but also provide ideal targets for translation into the clinical laboratory," write the authors.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Chest radiation may be useful for combatting advanced lung cancers

Chest radiation may be useful for combatting advanced ...

The addition of chest radiation reduces recurrence rate and, improves survival when added to chemo in extensive stage small-cell lung cancer.

Market changes needed as patients take on greater care costs

Market changes needed as patients take on greater ...

As consumers take on more costs of care, access to data for informed decisions is deemed crucial.

For black men with prostate cancer, watchful waiting may be unwise

For black men with prostate cancer, watchful waiting ...

For men with early-stage prostate cancer, watching waiting is not always the best course of action, especially for black patients.